Coherus Biosciences | CHRS - Trade Creditors


Coherus Biosciences reported $13.17M in Trade Creditors for its fiscal quarter ending in June of 2026.





Trade Creditors Change Date
AbbVie USD 33.3B 29.71B Jun/2026
Acadia Pharmaceuticals USD 16.33M 28.24M Sep/2026
Akebia Therapeutics USD 7.61M 1.81M Sep/2026
ALKERMES USD 107.69M 35.17M Sep/2026
Alnylam Pharmaceuticals USD 135.4M 27.38M Sep/2026
Amarin USD 40.43M 21.63M Sep/2026
Amgen USD 20.83B 17.97B Sep/2026
Baxter International USD 1.02B 10M Sep/2026
Biogen USD 430.3M 26.4M Sep/2026
BioMarin Pharmaceutical USD 946.11M 32.44M Sep/2026
Bristol-Myers Squibb USD 4.63B 470M Sep/2026
Coherus Biosciences USD 13.17M 1.69M Jun/2026
Eli Lilly USD 5.79B 319M Sep/2026
Fujifilm JPY 306B 10B Sep/2026
Gilead Sciences USD 934M 260M Sep/2026
Ironwood Pharmaceuticals USD 3.62M 2.7M Sep/2026
Merck USD 5.03B 1.2B Sep/2026
Myriad Genetics USD 30.4M 2.2M Jun/2026
Pacira USD 17.5M 4K Sep/2026
Perrigo USD 390.5M 9.9M Sep/2026
Pfizer USD 4.07B 511M Sep/2026
PTC Therapeutics USD 41.59M 1.14M Sep/2026
Regeneron Pharmaceuticals USD 1.14B 19M Sep/2026
Sarepta Therapeutics USD 45.7M 5.28M Sep/2026
Teva Pharmaceutical Industries USD 2.55B 170M Sep/2026
Vertex Pharmaceuticals USD 3.71B 99.2M Sep/2026
Xencor USD 6.65M 6M Sep/2026
Zoetis USD 419M 33M Sep/2026